查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1279852

2023-2030年全球軟組織肉瘤市場規模研究與預測，按治療方法、給藥途徑、終端用戶和區域分析。

Global Soft Tissue Sarcoma Market Size study & Forecast, by Treatment, By Route of Administration, By End-users, and Regional Analysis, 2023-2030
出版日期: | 出版商: Bizwit Research & Consulting LLP | 英文 | 商品交期: 2-3個工作天內

價格

軟組織肉瘤是一種源自身體軟組織的癌症，如肌肉、肌腱、脂肪、神經、血管和結締組織。身體軟組織中的腫塊或腫脹是軟組織肉瘤的一個跡象。身體上有許多不同的位置會發生軟組織肉瘤，這要透過活體組織切片來確定。全球市場的成長是由以下因素驅動的，如新型療法的不斷採用，對個性化醫療的日益關注，人口的不斷增加，以及醫療支出的增加，再加上有利的支付政策。

此外，癌症發病率的激增正成為全球市場成長的一個催化因素。根據世界衛生組織的資料，2020年，估計全球約有1930萬個新的癌症病例，預計到2040年將會增加並可能達到3030萬個病例。因此，上述這些因素推動軟組織肉瘤市場在估計期內的成長。此外，診斷和治療方案的不斷進步，以及對研究和開發的投資不斷增加，在預測的幾年裡呈現出各種有利的機會。然而，治療的高成本和軟組織肉瘤藥物的副作用阻礙整個2023-2030年預測期的市場成長。

全球軟組織肉瘤市場研究涵蓋的主要地區包括亞太、北美、歐洲、拉丁美洲和中東及非洲。由於對標靶治療的需求激增，對個性化醫療的關注度上升，以及存在完善的醫療設施，北美在2022年主導了市場。而亞太地區在預測期內預計將以最高的年複合成長率成長，原因是軟組織肉瘤的發病率上升，醫療支出增加，以及對研究和開發的投資增加等因素。

該研究的目的是定義近年來不同市場區隔和國家的市場規模，並預測未來幾年的價值。本報告旨在涵蓋參與研究的國家/地區的該產業的定性和定量方面。

本報告還提供了關於關鍵方面的詳細資訊，如驅動因素和挑戰，這將確定市場的未來成長。此外，還涵蓋了微觀市場的潛在機會，供利益相關者投資，並詳細分析了競爭格局和主要參與者的產品。

目錄

第一章：執行摘要

  • 市場簡介
  • 2020-2030年全球和細分市場的估計和預測
    • 2020-2030年，軟組織肉瘤市場，按地區分類
    • 2020-2030年，軟組織肉瘤市場，按治療方法分類
    • 2020-2030年，軟組織肉瘤市場，按給藥途徑分類
    • 2020-2030年，軟組織肉瘤市場，按終端用戶分類
  • 主要趨勢
  • 估算方法
  • 研究假設

第二章：全球軟組織肉瘤市場的定義和範圍

  • 本研究的目的
  • 市場定義和範圍
    • 產業演變
    • 研究的範圍
  • 研究涵蓋的年份
  • 貨幣兌換率

第三章：全球軟組織肉瘤市場動態

  • 軟組織肉瘤市場影響分析(2020-2030)
    • 市場驅動力
      • 新型療法的採用不斷增加
      • 癌症發病率的激增
    • 市場挑戰
      • 治療費用高
      • 軟組織肉瘤藥物的副作用
    • 市場機會
      • 診斷法和治療方案的不斷進步
      • 研究和開發方面的投資不斷增加

第四章：全球軟組織肉瘤市場產業分析

  • 波特五力模型
    • 供應商的議價能力
    • 買方的議價能力
    • 新進入者的威脅
    • 替代品的威脅
    • 競爭性的競爭
  • 波特五力影響分析
  • PEST分析
    • 政治
    • 經濟
    • 社會
    • 技術
    • 環境
    • 法律問題
  • 最佳投資機會
  • 最佳策略
  • COVID-19影響分析
  • 顛覆性趨勢
  • 產業專家的觀點
  • 分析師建議與結論

第五章：全球軟組織肉瘤市場，按治療方法分類

  • 市場簡介
  • 全球軟組織肉瘤市場，按治療方法，性能-潛力分析
  • 2020-2030年全球軟組織肉瘤市場按治療方法的估計和預測
  • 軟組織肉瘤市場，細項分析
    • 靶向治療
    • 化療
    • 抗血管生成藥物
    • 放射治療

第六章：全球軟組織肉瘤市場，按給藥途徑分類

  • 市場簡介
  • 按給藥途徑分類的全球軟組織肉瘤市場，表現- 潛力分析
  • 2020-2030年全球軟組織肉瘤市場按給藥途徑的估計和預測
  • 軟組織肉瘤市場，分項分析
    • 口服
    • 腸外
    • 其他途徑

第7章：全球軟組織肉瘤市場，按終端用戶分類

  • 市場簡介
  • 按終端用戶分類的全球軟組織肉瘤市場，表現- 潛力分析
  • 2020-2030年全球軟組織肉瘤市場按終端用戶估計和預測的情況
  • 軟組織肉瘤市場，子區隔分析
    • 醫院
    • 家庭護理
    • 專科中心
    • 其他

第八章：全球軟組織肉瘤市場，區域分析

  • 最領先的國家
  • 新興國家
  • 軟組織肉瘤市場，區域市場簡介
  • 北美洲
    • 美國
      • 2020-2030年，治療方法的細分估計和預測
      • 2020-2030年，給藥途徑的細分估計和預測
      • 2020-2030年終端用戶分類估計和預測
    • 加拿大
  • 歐洲軟組織肉瘤市場簡介
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 義大利
    • 歐洲其他地區
  • 亞太地區軟組織肉瘤市場簡介
    • 中國
    • 印度
    • 日本
    • 澳洲
    • 韓國
    • 亞太其他地區
  • 拉丁美洲軟組織肉瘤市場簡介
    • 巴西
    • 墨西哥
  • 中東和非洲
    • 沙烏地阿拉伯
    • 南非
    • 中東和非洲其他地區

第九章：競爭情報

  • 主要公司SWOT分析
    • 公司1
    • 公司2
    • 公司3
  • 頂級市場戰略
  • 公司簡介
    • F. Hoffmann-La Roche Ltd. (Switzerland)
      • 關鍵資訊
      • 概況
      • 財務（取決於資料的可用性）
      • 產品摘要
      • 近期發展情況
    • Mylan NV (US)
    • Teva Pharmaceutical Industries Ltd. (Israel)
    • Sanofi (France)
    • Pfizer Inc. (US)
    • GSK plc (UK)
    • Novartis AG (Switzerland)
    • Bayer AG (Germany)
    • Merck & Co., Inc. (US)
    • Sun Pharmaceutical Industries Ltd. (India)

第十章：研究過程

  • 研究過程
    • 資料探勘
    • 資料分析
    • 市場評估
    • 驗證
    • 出版
  • 研究屬性
  • 研究假設

Global Soft Tissue Sarcoma Market is valued at approximately USD XX billion in 2022 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2023-2030. Soft tissue sarcoma is a type of cancer that originates in the soft tissues of the body, such as muscles, tendons, fat, nerves, blood vessels, and connective tissues. A lump or swelling in a body's soft tissue is an indication of soft tissue sarcoma. There are many different locations on the body where soft tissue sarcomas develop, which is identified through biopsy. The global market growth is driven by factors such as the rising adoption of novel therapies, growing focus on personalized medicine, escalating population, and increasing healthcare expenditure, coupled with favorable reimbursement policies.

In addition, the surge in the incidences of cancer is acting as a catalyzing factor for market growth across the globe. According to the World Health Organization, in 2020, it was estimated that around 19.3 million new cancer cases were recorded globally, which is projected to increase and likely to reach 30.3 million cases by the year 2040. Thus, these aforementioned factors are propelling the growth of the soft tissue sarcoma market during the estimated period. Moreover, the rising advancements in diagnostics and treatment options, as well as increasing investments in research and development is presenting various lucrative opportunities over the forecasting years. However, the high cost of treatments and the side effects of soft tissue sarcoma drugs are hampering the market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Soft Tissue Sarcoma Market study include Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the surging demand for targeted therapies, rising focus on personalized medicine, and the presence of well-established healthcare facilities. Whereas, Asia Pacific is expected to grow with the highest CAGR during the forecast period, owing to factors such as the rising prevalence of soft tissue sarcoma, increasing healthcare expenditure, and growing investments in research and development.

Major market players included in this report are:

  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Mylan N.V. (U.S.)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • Sanofi (France)
  • Pfizer Inc. (U.S.)
  • GSK plc (U.K.)
  • Novartis AG (Switzerland)
  • Bayer AG (Germany)
  • Merck & Co., Inc. (U.S.)
  • Sun Pharmaceutical Industries Ltd. (India)

Recent Developments in the Market:

  • In 2019, Pfizer announced that Vitrakvi (larotrectinib) had received European Commission approval for the treatment of advanced soft tissue sarcoma. Vitrakvi - a targeted medication is available to patients whose tumours have a particular genetic mutation.
  • In 2019, Johnson & Johnson declared that the US Food and Drug Administration had authorized JNJ-4528 as a medication for the management of relapsed or refractory multiple myeloma. JNJ-4528 is a CAR-T cell therapy that is developed for use in the treatment of several malignancies, including some types of sarcomas.

Global Soft Tissue Sarcoma Market Report Scope:

  • Historical Data: - 2020 - 2021
  • Base Year for Estimation: - 2022
  • Forecast period: - 2023-2030
  • Report Coverage: - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
  • Segments Covered: - Treatment, Route of Administration, End-users, Region
  • Regional Scope: - North America; Europe; Asia Pacific; Latin America; Middle East & Africa
  • Customization Scope: - Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below.

By Treatment:

  • Targeted Therapy
  • Chemotherapy
  • Anti-Angiogenesis Drugs
  • Radiation Therapy

By Route of Administration:

  • Oral
  • Parenteral
  • Others

By End-users:

  • Hospitals
  • Homecare
  • Speciality Centres
  • Others

By Region:

  • North America
  • U.S.
  • Canada
  • Europe
  • UK
  • Germany
  • France
  • Spain
  • Italy
  • ROE
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • RoAPAC
  • Latin America
  • Brazil
  • Mexico
  • Middle East & Africa
  • Saudi Arabia
  • South Africa
  • Rest of Middle East & Africa

Table of Contents

Chapter 1. Executive Summary

  • 1.1. Market Snapshot
  • 1.2. Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Billion)
    • 1.2.1. Soft Tissue Sarcoma Market, by Region, 2020-2030 (USD Billion)
    • 1.2.2. Soft Tissue Sarcoma Market, by Treatment, 2020-2030 (USD Billion)
    • 1.2.3. Soft Tissue Sarcoma Market, by Route of Administration, 2020-2030 (USD Billion)
    • 1.2.4. Soft Tissue Sarcoma Market, by End-users, 2020-2030 (USD Billion)
  • 1.3. Key Trends
  • 1.4. Estimation Methodology
  • 1.5. Research Assumption

Chapter 2. Global Soft Tissue Sarcoma Market Definition and Scope

  • 2.1. Objective of the Study
  • 2.2. Market Definition & Scope
    • 2.2.1. Industry Evolution
    • 2.2.2. Scope of the Study
  • 2.3. Years Considered for the Study
  • 2.4. Currency Conversion Rates

Chapter 3. Global Soft Tissue Sarcoma Market Dynamics

  • 3.1. Soft Tissue Sarcoma Market Impact Analysis (2020-2030)
    • 3.1.1. Market Drivers
      • 3.1.1.1. Rising adoption of novel therapies
      • 3.1.1.2. Surge in the incidences of cancer
    • 3.1.2. Market Challenges
      • 3.1.2.1. High cost of treatments
      • 3.1.2.2. Side effects of soft tissue sarcoma drugs
    • 3.1.3. Market Opportunities
      • 3.1.3.1. Rising advancements in diagnostics and treatment options
      • 3.1.3.2. Increasing investments in research and development

Chapter 4. Global Soft Tissue Sarcoma Market Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
  • 4.2. Porter's 5 Force Impact Analysis
  • 4.3. PEST Analysis
    • 4.3.1. Political
    • 4.3.2. Economical
    • 4.3.3. Social
    • 4.3.4. Technological
    • 4.3.5. Environmental
    • 4.3.6. Legal
  • 4.4. Top investment opportunity
  • 4.5. Top winning strategies
  • 4.6. COVID-19 Impact Analysis
  • 4.7. Disruptive Trends
  • 4.8. Industry Expert Perspective
  • 4.9. Analyst Recommendation & Conclusion

Chapter 5. Global Soft Tissue Sarcoma Market, by Treatment

  • 5.1. Market Snapshot
  • 5.2. Global Soft Tissue Sarcoma Market by Treatment, Performance - Potential Analysis
  • 5.3. Global Soft Tissue Sarcoma Market Estimates & Forecasts by Treatment 2020-2030 (USD Billion)
  • 5.4. Soft Tissue Sarcoma Market, Sub Segment Analysis
    • 5.4.1. Targeted Therapy
    • 5.4.2. Chemotherapy
    • 5.4.3. Anti-Angiogenesis Drugs
    • 5.4.4. Radiation Therapy

Chapter 6. Global Soft Tissue Sarcoma Market, by Route of Administration

  • 6.1. Market Snapshot
  • 6.2. Global Soft Tissue Sarcoma Market by Route of Administration, Performance - Potential Analysis
  • 6.3. Global Soft Tissue Sarcoma Market Estimates & Forecasts by Route of Administration 2020-2030 (USD Billion)
  • 6.4. Soft Tissue Sarcoma Market, Sub Segment Analysis
    • 6.4.1. Oral
    • 6.4.2. Parenteral
    • 6.4.3. Others

Chapter 7. Global Soft Tissue Sarcoma Market, by End-users

  • 7.1. Market Snapshot
  • 7.2. Global Soft Tissue Sarcoma Market by End-users, Performance - Potential Analysis
  • 7.3. Global Soft Tissue Sarcoma Market Estimates & Forecasts by End-users 2020-2030 (USD Billion)
  • 7.4. Soft Tissue Sarcoma Market, Sub Segment Analysis
    • 7.4.1. Hospitals
    • 7.4.2. Homecare
    • 7.4.3. Speciality Centres
    • 7.4.4. Others

Chapter 8. Global Soft Tissue Sarcoma Market, Regional Analysis

  • 8.1. Top Leading Countries
  • 8.2. Top Emerging Countries
  • 8.3. Soft Tissue Sarcoma Market, Regional Market Snapshot
  • 8.4. North America Soft Tissue Sarcoma Market
    • 8.4.1. U.S. Soft Tissue Sarcoma Market
      • 8.4.1.1. Treatment breakdown estimates & forecasts, 2020-2030
      • 8.4.1.2. Route of Administration breakdown estimates & forecasts, 2020-2030
      • 8.4.1.3. End-users breakdown estimates & forecasts, 2020-2030
    • 8.4.2. Canada Soft Tissue Sarcoma Market
  • 8.5. Europe Soft Tissue Sarcoma Market Snapshot
    • 8.5.1. U.K. Soft Tissue Sarcoma Market
    • 8.5.2. Germany Soft Tissue Sarcoma Market
    • 8.5.3. France Soft Tissue Sarcoma Market
    • 8.5.4. Spain Soft Tissue Sarcoma Market
    • 8.5.5. Italy Soft Tissue Sarcoma Market
    • 8.5.6. Rest of Europe Soft Tissue Sarcoma Market
  • 8.6. Asia-Pacific Soft Tissue Sarcoma Market Snapshot
    • 8.6.1. China Soft Tissue Sarcoma Market
    • 8.6.2. India Soft Tissue Sarcoma Market
    • 8.6.3. Japan Soft Tissue Sarcoma Market
    • 8.6.4. Australia Soft Tissue Sarcoma Market
    • 8.6.5. South Korea Soft Tissue Sarcoma Market
    • 8.6.6. Rest of Asia Pacific Soft Tissue Sarcoma Market
  • 8.7. Latin America Soft Tissue Sarcoma Market Snapshot
    • 8.7.1. Brazil Soft Tissue Sarcoma Market
    • 8.7.2. Mexico Soft Tissue Sarcoma Market
  • 8.8. Middle East & Africa Soft Tissue Sarcoma Market
    • 8.8.1. Saudi Arabia Soft Tissue Sarcoma Market
    • 8.8.2. South Africa Soft Tissue Sarcoma Market
    • 8.8.3. Rest of Middle East & Africa Soft Tissue Sarcoma Market

Chapter 9. Competitive Intelligence

  • 9.1. Key Company SWOT Analysis
    • 9.1.1. Company 1
    • 9.1.2. Company 2
    • 9.1.3. Company 3
  • 9.2. Top Market Strategies
  • 9.3. Company Profiles
    • 9.3.1. F. Hoffmann-La Roche Ltd. (Switzerland)
      • 9.3.1.1. Key Information
      • 9.3.1.2. Overview
      • 9.3.1.3. Financial (Subject to Data Availability)
      • 9.3.1.4. Product Summary
      • 9.3.1.5. Recent Developments
    • 9.3.2. Mylan N.V. (U.S.)
    • 9.3.3. Teva Pharmaceutical Industries Ltd. (Israel)
    • 9.3.4. Sanofi (France)
    • 9.3.5. Pfizer Inc. (U.S.)
    • 9.3.6. GSK plc (U.K.)
    • 9.3.7. Novartis AG (Switzerland)
    • 9.3.8. Bayer AG (Germany)
    • 9.3.9. Merck & Co., Inc. (U.S.)
    • 9.3.10. Sun Pharmaceutical Industries Ltd. (India)

Chapter 10. Research Process

  • 10.1. Research Process
    • 10.1.1. Data Mining
    • 10.1.2. Analysis
    • 10.1.3. Market Estimation
    • 10.1.4. Validation
    • 10.1.5. Publishing
  • 10.2. Research Attributes
  • 10.3. Research Assumption

LIST OF TABLES

  • TABLE 1. Global Soft Tissue Sarcoma Market, report scope
  • TABLE 2. Global Soft Tissue Sarcoma Market estimates & forecasts by Region 2020-2030 (USD Billion)
  • TABLE 3. Global Soft Tissue Sarcoma Market estimates & forecasts by Treatment 2020-2030 (USD Billion)
  • TABLE 4. Global Soft Tissue Sarcoma Market estimates & forecasts by Route of Administration 2020-2030 (USD Billion)
  • TABLE 5. Global Soft Tissue Sarcoma Market estimates & forecasts by End-users 2020-2030 (USD Billion)
  • TABLE 6. Global Soft Tissue Sarcoma Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 7. Global Soft Tissue Sarcoma Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 8. Global Soft Tissue Sarcoma Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 9. Global Soft Tissue Sarcoma Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 10. Global Soft Tissue Sarcoma Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 11. Global Soft Tissue Sarcoma Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 12. Global Soft Tissue Sarcoma Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 13. Global Soft Tissue Sarcoma Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 14. Global Soft Tissue Sarcoma Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 15. Global Soft Tissue Sarcoma Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 16. U.S. Soft Tissue Sarcoma Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 17. U.S. Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 18. U.S. Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 19. Canada Soft Tissue Sarcoma Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 20. Canada Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 21. Canada Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 22. UK Soft Tissue Sarcoma Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 23. UK Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 24. UK Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 25. Germany Soft Tissue Sarcoma Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 26. Germany Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 27. Germany Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 28. France Soft Tissue Sarcoma Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 29. France Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 30. France Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 31. Italy Soft Tissue Sarcoma Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 32. Italy Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 33. Italy Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 34. Spain Soft Tissue Sarcoma Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 35. Spain Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 36. Spain Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 37. RoE Soft Tissue Sarcoma Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 38. RoE Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 39. RoE Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 40. China Soft Tissue Sarcoma Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 41. China Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 42. China Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 43. India Soft Tissue Sarcoma Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 44. India Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 45. India Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 46. Japan Soft Tissue Sarcoma Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 47. Japan Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 48. Japan Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 49. South Korea Soft Tissue Sarcoma Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 50. South Korea Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 51. South Korea Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 52. Australia Soft Tissue Sarcoma Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 53. Australia Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 54. Australia Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 55. RoAPAC Soft Tissue Sarcoma Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 56. RoAPAC Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 57. RoAPAC Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 58. Brazil Soft Tissue Sarcoma Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 59. Brazil Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 60. Brazil Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 61. Mexico Soft Tissue Sarcoma Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 62. Mexico Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 63. Mexico Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 64. RoLA Soft Tissue Sarcoma Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 65. RoLA Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 66. RoLA Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 67. Saudi Arabia Soft Tissue Sarcoma Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 68. South Africa Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 69. RoMEA Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 70. List of secondary sources, used in the study of global Soft Tissue Sarcoma Market
  • TABLE 71. List of primary sources, used in the study of global Soft Tissue Sarcoma Market
  • TABLE 72. Years considered for the study
  • TABLE 73. Exchange rates considered

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

LIST OF FIGURES

List of figures

  • FIG 1. Global Soft Tissue Sarcoma Market, research methodology
  • FIG 2. Global Soft Tissue Sarcoma Market, Market estimation techniques
  • FIG 3. Global Market size estimates & forecast methods
  • FIG 4. Global Soft Tissue Sarcoma Market, key trends 2022
  • FIG 5. Global Soft Tissue Sarcoma Market, growth prospects 2023-2030
  • FIG 6. Global Soft Tissue Sarcoma Market, porters 5 force model
  • FIG 7. Global Soft Tissue Sarcoma Market, pest analysis
  • FIG 8. Global Soft Tissue Sarcoma Market, value chain analysis
  • FIG 9. Global Soft Tissue Sarcoma Market by segment, 2020 & 2030 (USD Billion)
  • FIG 10. Global Soft Tissue Sarcoma Market by segment, 2020 & 2030 (USD Billion)
  • FIG 11. Global Soft Tissue Sarcoma Market by segment, 2020 & 2030 (USD Billion)
  • FIG 12. Global Soft Tissue Sarcoma Market by segment, 2020 & 2030 (USD Billion)
  • FIG 13. Global Soft Tissue Sarcoma Market by segment, 2020 & 2030 (USD Billion)
  • FIG 14. Global Soft Tissue Sarcoma Market, regional snapshot 2020 & 2030
  • FIG 15. North America Soft Tissue Sarcoma Market 2020 & 2030 (USD Billion)
  • FIG 16. Europe Soft Tissue Sarcoma Market 2020 & 2030 (USD Billion)
  • FIG 17. Asia pacific Soft Tissue Sarcoma Market 2020 & 2030 (USD Billion)
  • FIG 18. Latin America Soft Tissue Sarcoma Market 2020 & 2030 (USD Billion)
  • FIG 19. Middle East & Africa Soft Tissue Sarcoma Market 2020 & 2030 (USD Billion)

List of tables and figures and dummy in nature, final lists may vary in the final deliverable